FDA
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
-
-
-
-
-
-
-
Corbus receives FDA alignment on registration path for cancer drug CRB-701
-
-
-
-
-
-
-
Corbus Pharmaceuticals to present CRB-701 cancer drug data at ESMO
-
-
-
-
-
-
-
Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at H.C. Wainwright
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
-
-
-
-
-
-
-
Corbus Pharma (CRBP) Adds Clinical Stage Nectin-4 targeting Antibody Drug Conjugate
-
327,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

